
Artiva Biotherapeutics fell 0.8% from $3.89 to $3.86, behind the S&P 500's +11.0%. Its worst day was Oct 27 (−30.7%), and its low came Dec 10 at $3.07.
Story events cover the past 12 months · Times ET
Nov 18, 2025 – Nov 17, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Artiva Biotherapeutics closed at its lowest level of the year, 21.1% below where the year started.
−1.6% · S&P 500 +0.7%
EPS of $-0.84 missed the $-0.83 estimate on $0.00 revenue.
+6.5% · S&P 500 −0.2%
Artiva Biotherapeutics closed at its highest level of the year, 244.2% above where the year started.
+6.7% · S&P 500 −0.2%
EPS of $-0.95 missed the $-0.85 estimate on $0.00 revenue.
−13.0% · S&P 500 +0.8%
EPS of $-0.63 beat the $-0.64 estimate on $0.00 revenue.
−2.7% · S&P 500 +0.6%
Artiva Biotherapeutics shares fell 30.7%, while the S&P 500 rose 0.6%.
−30.7%, the year's worst day · S&P 500 +0.6%
EPS of $-0.56 missed the $-0.54 estimate on $0.00 revenue.
+0.2% · S&P 500 +1.3%
Where it ended: a close of $3.86 on Nov 17, 2026. Up next: Q4 2026 earnings on Mar 9, 2027 (EPS est. $-0.24).
Nothing in the past 12 months.
All ARTV dividend history